What Inhibrx Biosciences Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 20 | 20 |
| Sells | 5 | 5 |
| Total trades | 25 | 25 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 62,540 | 62,540 |
| Disposed | 2,500 | 2,500 |
| Net activity | +60,040 | +60,040 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +100 | $85.76 | +$8.58K | 170,000 |
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +2,451 | $85.00 | +$208K | 169,900 |
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +2,449 | $84.07 | +$206K | 167,449 |
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +100 | $85.76 | +$8.58K | 745,588 |
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +2,470 | $85.00 | +$210K | 745,488 |
| Lappe Mark | Chief Executive Officer | Oct 14 | Open-market buy · P | +2,470 | $84.07 | +$208K | 743,018 |
| Lappe Mark | Chief Executive Officer | Sep 28 | Open-market buy · P | +3,000 | $101.70 | +$305K | 740,548 |
| Lappe Mark | Chief Executive Officer | Sep 28 | Open-market buy · P | +1,500 | $98.88 | +$148K | 737,548 |
| Lappe Mark | Chief Executive Officer | Sep 25 | Open-market buy · P | +2,176 | $99.60 | +$217K | 736,048 |
| Lappe Mark | Chief Executive Officer | Sep 25 | Open-market buy · P | +3,324 | $98.87 | +$329K | 733,872 |
| Kayyem Jon Faiz | Director | Sep 23 | Open-market buy · P | +5,000 | $100.00 | +$500K | 434,360 |
| Kayyem Jon Faiz | Director | Sep 16 | Open-market buy · P | +5,000 | $100.00 | +$500K | 429,360 |
| Manhard Kimberly | Director | Sep 15 | Open-market sale · S | −500 | $105.05 | −$52.5K | 7,500 |
| Manhard Kimberly | Director | Sep 14 | Open-market sale · S | −500 | $110.26 | −$55.1K | 8,000 |
| Manhard Kimberly | Director | Sep 11 | Open-market sale · S | −500 | $111.78 | −$55.9K | 8,500 |
| Manhard Kimberly | Director | Sep 09 | Open-market sale · S | −500 | $115.80 | −$57.9K | 9,000 |
| Kayyem Jon Faiz | Director | Sep 08 | Open-market buy · P | +5,000 | $113.52 | +$568K | 424,360 |
| Lappe Mark | Chief Executive Officer | Sep 08 | Open-market buy · P | +9,681 | $112.28 | +$1.09M | 730,548 |
| Lappe Mark | Chief Executive Officer | Sep 08 | Open-market buy · P | +1,219 | $111.88 | +$136K | 720,867 |
| Lappe Mark | Chief Executive Officer | Sep 08 | Open-market buy · P | +500 | $108.24 | +$54.1K | 719,648 |
Loading...